{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:59:49Z","timestamp":1788951589674,"version":"build-2803163510"},"reference-count":29,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of Classical Hodgkin Lymphoma patients wIth Primary treatment failure and analySis of outcomEs) is a multicenter retrospective cohort of patients with PTF-cHL (aged \u226515 years) diagnosed on or after 1 January 2005, at 15 US medical centers. PTF was defined as 1 of the following patterns of failure: (1) progressive disease by imaging during or within 6\u00a0weeks of completion of frontline chemotherapy (primary progression [PP]); (2) partial response (PR) or stable disease (SD) by imaging after completion of frontline treatment (PR\/SD); (3)\u00a0progression of disease by imaging (and confirmed by biopsy) within 12\u00a0months of frontline therapy completion after prior documentation of complete response (CR; early relapse [ER]). A total of 478 patients were included in the analysis. Among these, 217 (45%) were PP, 86 (18%) were PR\/SD, and 175 (37%) were ER. The 6-month and 1-year cumulative incidence of nonrelapse mortality after auto-HCT were 0.9% and 1.1%, respectively. The median progression-free survival (PFS) and overall survival (OS) after auto-HCT were 4.33 and 10.09 years, respectively. Although those not in CR at the time of auto-HCT were associated with inferior PFS and OS, advanced age and diagnosis before 2011 were associated with inferior OS. This study showcases the safety and long-term efficacy of auto-HCT, even in patients with high-risk disease who are traditionally considered chemotherapy refractory, and will serve as a benchmark for the ongoing transplant vs no transplant trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013743","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T19:04:56Z","timestamp":1725044696000},"page":"5458-5466","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"},{"name":"2Division of Hematology and Hematologic Malignancies, Department of Medicine, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Vaughn","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"},{"name":"4Department of Medicine, Smilow Cancer Hospital, Yale New Haven, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"},{"name":"6Department of Medicine, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA"},{"name":"8Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Case Western Reserve, Cleveland, OH"},{"name":"10Department of Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarsheen K.","family":"Sethi","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Smilow Cancer Hospital, Yale New Haven, New Haven, CT"},{"name":"11Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Bello","sequence":"additional","affiliation":[{"name":"13Department of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"13Department of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin K.","family":"Kothari","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Smilow Cancer Hospital, Yale New Haven, New Haven, CT"},{"name":"14Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"14Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Lansigan","sequence":"additional","affiliation":[{"name":"15Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha J.","family":"Glenn","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Hematologic Malignancies, Department of Medicine, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"16Department of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"Sorge","sequence":"additional","affiliation":[{"name":"17Department of Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Christian","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"18Department of Medicine, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"19Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-3798","authenticated-orcid":false,"given":"Ana C.","family":"Xavier","sequence":"additional","affiliation":[{"name":"20Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"1","key":"2024111214203588300_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/hematology.2021000255","article-title":"Controversies in the management of early-stage Hodgkin lymphoma","volume":"2021","author":"Blum","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"17","key":"2024111214203588300_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024111214203588300_bib3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024111214203588300_bib4","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024111214203588300_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8852","key":"2024111214203588300_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"2024111214203588300_bib7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"36","key":"2024111214203588300_bib8","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM Study Group","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2024111214203588300_bib9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024111214203588300_bib10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma","volume":"19","author":"Hahn","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024111214203588300_bib11","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Martinez","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"2024111214203588300_bib12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A\u00a0prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024111214203588300_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.14245","article-title":"Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation","volume":"175","author":"Shah","year":"2016","journal-title":"Br J Haematol"},{"issue":"27","key":"2024111214203588300_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024111214203588300_bib15","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"2024111214203588300_bib16","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2024111214203588300_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2009.07645.x","article-title":"Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing\/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy","volume":"145","author":"Castagna","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"2024111214203588300_bib18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bbmt.2010.02.022","article-title":"Phase I\/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma","volume":"16","author":"Arai","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024111214203588300_bib19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2024111214203588300_bib20","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2024111214203588300_bib21","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024111214203588300_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2014","article-title":"High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors","volume":"31","author":"Cocorocchio","year":"2013","journal-title":"Hematol Oncol"},{"issue":"3","key":"2024111214203588300_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024111214203588300_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1179\/1607845412Y.0000000063","article-title":"Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey","volume":"18","author":"Sucak","year":"2013","journal-title":"Hematology"},{"issue":"6","key":"2024111214203588300_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol"},{"issue":"7","key":"2024111214203588300_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood.2020007900","article-title":"How I incorporate novel agents into the treatment of classical Hodgkin lymphoma","volume":"138","author":"Epperla","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024111214203588300_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40164-022-00360-4","article-title":"Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches","volume":"11","author":"Hanel","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2024111214203588300_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/hematology.2021000256","article-title":"Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors","volume":"2021","author":"Epperla","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2024111214203588300_bib29","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1080\/10428194.2021.1927016","article-title":"Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma","volume":"62","author":"Fakhri","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5458\/2312469\/blooda_adv-2024-013743-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5458\/2312469\/blooda_adv-2024-013743-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T14:21:03Z","timestamp":1731421263000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/21\/5458\/517649\/Evaluation-of-prognostic-factors-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013743","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}